Published in Ann Rheum Dis on November 01, 2002
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis (2003) 1.44
Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis (2003) 1.28
A disease activity score for polymyalgia rheumatica. Ann Rheum Dis (2004) 1.22
Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis (2004) 1.17
Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis (2008) 1.15
Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis (2004) 1.06
Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography. Clin Rheumatol (2007) 0.92
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis (2015) 0.86
Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol (2003) 0.85
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clin Rheumatol (2016) 0.76
Ultrasound Detection of Salmonella Septic Arthritis in a Rheumatoid Arthritis Patient on Anti-TNF Treatment. J Investig Med High Impact Case Rep (2014) 0.75
Welcome to the Journal of Immune Based Therapies and Vaccines (JIBTV). J Immune Based Ther Vaccines (2003) 0.75
[Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies]. Wien Med Wochenschr (2003) 0.75
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Clinical guidelines: developing guidelines. BMJ (1999) 6.01
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med (2000) 4.76
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum (2001) 4.60
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 3.78
Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet (2001) 2.95
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum (2000) 1.79
Retracted Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum (2001) 1.77
Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am (1998) 1.40
Etanercept: a review of its use in rheumatoid arthritis. Drugs (1999) 1.32
Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs (2000) 1.30
Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum (2001) 1.25
Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther (1999) 1.12
Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum (2002) 1.12
Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol (1996) 1.08
Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis (1999) 1.06
Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.00
Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis (1999) 0.96
Remission of Behçet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis (2002) 0.95
Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis (1999) 0.95
Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy. J Rheumatol (2001) 0.92
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2003) 7.95
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) (2004) 4.56
Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis (2003) 4.36
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med (2001) 4.31
Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis (2001) 4.18
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis (2007) 3.89
Influence of non-inherited maternal HLA antigens on occurrence of rheumatoid arthritis. Lancet (1993) 3.87
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum (1997) 3.80
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Epidermal Langerhans cells express Ia antigens. Nature (1977) 3.51
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis (2003) 3.43
Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum (1999) 3.42
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis (2008) 3.42
Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 3.41
Macrophages in rheumatoid arthritis. Arthritis Res (2000) 3.40
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol (1983) 3.26
Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum (1999) 3.08
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res (1994) 2.96
Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods (1988) 2.84
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis (2001) 2.69
[Polymyalgia rheumatica and temporal arteritis]. Ned Tijdschr Geneeskd (2005) 2.68
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.66
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis (2005) 2.62
Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum (2009) 2.57
Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum (1986) 2.56
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.51
Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ (1998) 2.51
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis (2005) 2.48
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
Synovial fluid T cell reactivity against 65 kD heat shock protein of mycobacteria in early chronic arthritis. Lancet (1988) 2.43
Detection of bacterial DNA in joint samples from patients with undifferentiated arthritis and reactive arthritis, using polymerase chain reaction with universal 16S ribosomal RNA primers. Arthritis Rheum (1998) 2.41
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol (1993) 2.40
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis (2008) 2.36
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) (2006) 2.36
Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med (2010) 2.30
Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis. Arthritis Rheum (1981) 2.30
Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet (1996) 2.30
Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol (2014) 2.28
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum (2006) 2.28
Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis (2008) 2.27
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Citrullination is an inflammation-dependent process. Ann Rheum Dis (2006) 2.25
Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum (1998) 2.24
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis (2005) 2.23
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2000) 2.19
Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2008) 2.17
Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum (2000) 2.14
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2001) 2.11
Identification of three major synovial lining cell populations by monoclonal antibodies directed to Ia antigens and antigens associated with monocytes/macrophages and fibroblasts. Scand J Immunol (1983) 2.10
Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum (2007) 2.10